Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.
暂无分享,去创建一个
Shibu Yooseph | Victor Seguritan | Rohit Loomba | Claude B. Sirlin | Chi-Hua Chen | Nicholas J. Schork | Lauren M. Brinkac | Niels Klitgord | Weizhong Li | Karen E. Nelson | David A. Brenner | Parambir S. Dulai | J. Venter | J. Venter | S. Yooseph | N. Schork | Niels Klitgord | D. Brenner | K. Nelson | C. Sirlin | Chi-Hua Chen | L. Brinkac | W. Biggs | S. Highlander | Marcus B. Jones | Weizhong Li | R. Loomba | R. Bettencourt | P. Dulai | T. Long | B. Schnabl | V. Seguritan | William H. Biggs | Richele Bettencourt | A. Bhatt | Cyrielle Caussy | Bernd Schnabl | Sarah K. Highlander | Cyrielle Caussy | J. Craig Venter | Tao Long | Archana Bhatt | C. Caussy | D. Brenner | Shibu Yooseph
[1] V. Wong,et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.
[2] D. Brenner,et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood , 2016, Hepatology.
[3] F. Servant,et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis , 2016, Hepatology.
[4] Rohit Loomba,et al. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. , 2016, Journal of hepatology.
[5] N. Schork,et al. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study , 2016, Hepatology.
[6] J. Chiang,et al. Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis[S] , 2016, Journal of Lipid Research.
[7] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[8] J. Bajaj,et al. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? , 2016, Gastroenterology.
[9] Xin Liu,et al. Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge , 2016, Molecular medicine reports.
[10] Lawrence A. David,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota , 2016, Hepatology.
[11] R. Loomba,et al. Targeting Dysbiosis for the Treatment of Liver Disease , 2016, Seminars in Liver Disease.
[12] J. Borén,et al. Confounding Effects of Metformin on the Human Gut Microbiome in Type 2 Diabetes. , 2016, Cell metabolism.
[13] Hong-wei Zhang,et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults , 2016, Scientific Reports.
[14] Jun Wang,et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota , 2015, Nature.
[15] N. Schork,et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. , 2015, Gastroenterology.
[16] J. Venter,et al. Library preparation methodology can influence genomic and functional predictions in human microbiome research , 2015, Proceedings of the National Academy of Sciences.
[17] Manuel L Gonzalez-Garay,et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health , 2015, Proceedings of the National Academy of Sciences.
[18] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[19] Mary E Rinella,et al. Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.
[20] S. Subramaniam,et al. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study , 2015, Gut.
[21] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[22] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] Beiwen Zheng,et al. Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.
[24] Andmorgan R. Fisher,et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. , 2014, Journal of hepatology.
[25] G. Svegliati-Baroni,et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice , 2014, Hepatology.
[26] R. Schwabe,et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis , 2014, Gut.
[27] Jens Roat Kultima,et al. Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2015, Nature.
[28] Rohit Loomba,et al. The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.
[29] H. Nittono,et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. , 2013, Journal of Hepatology.
[30] Lixin Zhu,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.
[31] Richard A. Flavell,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.
[32] Giorgio Saracco,et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.
[33] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[34] Vincent Wai-Sun Wong,et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.
[35] B. Haas,et al. A Catalog of Reference Genomes from the Human Microbiome , 2010, Science.
[36] W. R. Wikoff,et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.
[37] B. Roe,et al. A core gut microbiome in obese and lean twins , 2008, Nature.
[38] Yosuke Osawa,et al. TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.
[39] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .
[40] T. Takagi,et al. MetaGene: prokaryotic gene finding from environmental genome shotgun sequences , 2006, Nucleic acids research.
[41] M. Pop,et al. Metagenomic Analysis of the Human Distal Gut Microbiome , 2006, Science.
[42] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[43] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[44] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[45] Peter D. Karp,et al. The Pathway Tools software , 2002, ISMB.
[46] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[47] C. W. Moss,et al. Production of hydrocinnamic acid by clostridia. , 1970, Applied microbiology.